Multiple adenocarcinomas in intrathoracic upside-down stomach.

T. Namikawa,Michiya Kobayashi,K. Hanazaki

DOI: https://doi.org/10.1016/j.gie.2015.02.007

IF: 10.396

2015-08-01

Gastrointestinal Endoscopy

Abstract:

What problem does this paper attempt to address?

Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma

Vikram S. Pothuri,Graham D. Hogg,Leah Conant,Nicholas Borcherding,C. Alston James,Jacqueline Mudd,Greg Williams,Yongwoo David Seo,William G. Hawkins,Venu G. Pillarisetty,David G. DeNardo,Ryan C. Fields

DOI: https://doi.org/10.1080/2162402x.2024.2320411

2024-03-16

OncoImmunology

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is refractory to immune checkpoint inhibitor therapy. However, intratumoral T-cell infiltration correlates with improved overall survival (OS). Herein, we characterized the diversity and antigen specificity of the PDAC T-cell receptor (TCR) repertoire to identify novel immune-relevant biomarkers. Demographic, clinical, and TCR-beta sequencing data were collated from 353 patients across three cohorts that underwent surgical resection for PDAC. TCR diversity was calculated using Shannon Wiener index, Inverse Simpson index, and "True entropy." Patients were clustered by shared repertoire specificity. TCRs predictive of OS were identified and their associated transcriptional states were characterized by single-cell RNAseq. In multivariate Cox regression models controlling for relevant covariates, high intratumoral TCR diversity predicted OS across multiple cohorts. Conversely, in peripheral blood, high abundance of T-cells, but not high diversity, predicted OS. Clustering patients based on TCR specificity revealed a subset of TCRs that predicts OS. Interestingly, these TCR sequences were more likely to encode CD8 + effector memory and CD4 + T-regulatory (Tregs) T-cells, all with the capacity to recognize beta islet-derived autoantigens. As opposed to T-cell abundance, intratumoral TCR diversity was predictive of OS in multiple PDAC cohorts, and a subset of TCRs enriched in high-diversity patients independently correlated with OS. These findings emphasize the importance of evaluating peripheral and intratumoral TCR repertoires as distinct and relevant biomarkers in PDAC.

oncology,immunology
312P Identification of Neoantigen-Specific T Cell Response and Anti-Tumour Immunity in Pancreatic Cancer

X. Du,W. Lin,X. Lyu,Y. Huang,K. He,J. Cao,L. Teng

DOI: https://doi.org/10.1016/j.annonc.2020.10.306

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Pancreatic cancer is a highly aggressive malignancy with relatively low morbidity, which is marked by insidious clinical symptoms but rapid development. The therapeutic options of PC are limited for the insensitivity of traditional chemoradiotherapies. The neoantigen-based vaccine is an emerging tumor immune therapeutic option, but limited evidence proved the efficient therapeutic response in pancreatic cancer. Whole exome sequencing and bioinformatic analysis as well as quantitative real-time PCR of our previously established human pancreatic cancer cell line were performed to identify neoantigen candidates. The Immunogenicity of prioritized neoantigens was evaluated by analyzing the INF-γ secretion of neoantigen-induced T cell. The antitumor immunity of neoantigen-specific Cytotoxic T cells was examined by the cytotoxicity assay. The commutative analysis and quantitative real-time PCR identified 13 candidate neoantigens of our previously established human pancreatic cancer cell line PDXPC1 which was confirm as a multi-drug resistant cancer cell line. 4 of 13 candidate neoantigens can be recognized by the immune system and induced strong neoantigen-specific T cell response. The cytotoxic activities mediated by neoantigen-specific T cells significantly inhibited the growth of PDXPC1 tumor cells. Noteworthily, T cells recognized 3 of 4 neoepitopes via the presentation of dendritic cells. In conclusion, the neoantigens selected by the next generation sequencing and computational algorithm can target the tumor inhibition of pancreatic cancer, which represent a new powerful approach for multidrug resistance and suggest a general strategy for personalized cancer immunotherapy in pancreatic cancer.
Abstract 3241: Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy

Joseph A. Tandurella,Jacob T. Mitchell,Janelle M. Montagne,Eric Christenson,Qingfeng Zhu,Ludmilla V. Danilova,Alexander V. Favorov,Won J. Ho,Luciane T. Kagohara,Melanie Loth,Su Jin Lim,Rui Zheng,Jessica Gai,Sarah Mitchell,Dimitrios N. Sidiropoulos,Wenpin Hou,Yao Xu,Hao Wang,Jacquelyn W. Zimmerman,Srinivasan Yegnasubramanian,Robert Anders,Elizabeth M. Jaffee,Lei Zheng,Elana J. Fertig

DOI: https://doi.org/10.1158/1538-7445.am2023-3241

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Introduction: Pancreatic ductal adenocarcinomas (PDACs) are immunogenically “cold” tumors that lack effector T cell infiltration associated with immune checkpoint inhibitor (ICI) responsiveness. Neoadjuvant immunotherapy clinical trials facilitate understanding of the complexities of combination treatment strategies on immunosuppressive mechanisms. Our recent multi-omics analysis of a neoadjuvant trial comparing the GVAX vaccine alone or with nivolumab and supporting preclinical data uncovered crosstalk between CD8+CD137+ T cells and neutrophils as an axis for therapeutic intervention. These studies have formed the foundation for the addition of the CD137 agonist, urelumab, to our combination regimen to improve T cell activation in PDACs. Methods: Patients were enrolled on NCT02451982 and initiated treatment 2 weeks prior to surgical resection. We compared specimens from 3 treatment arms for downstream analysis: Arm A: an allogeneic whole cell vaccine, GVAX (n=7); Arm B: GVAX and nivolumab (n=4); Arm C: GVAX, nivolumab, and urelumab (n=4). Samples underwent dissociation and Percoll separation to enrich for immune cells, followed by single-cell RNA- and TCR-seq using 10X Genomics. Computational analysis was performed for cell type classification with Seurat, differential expression with DESeq2 of pseudobulk data, cell-cell communication with Domino, and TCR-seq analysis with scRepertoire. Results: Single-cell RNA-seq analysis identified changes in immune cell proportions and immune cell states across treatment arms. Alignment of scTCR-seq to RNA data showed greater CD8+ T cell expansion following triple agent therapy. Gene set enrichment identified changes in CD8+ T cell, tumor associated macrophage (TAM), and B cell responses to cytokine signaling, locomotion, amino acid metabolism, and cell adhesion pathways in Arm C. Domino analysis demonstrated increases in the naïve T cell signal CCR7 in Arm A and integrin ligand signal ICAM1 in Arm C between the CD8+ T cells and other cell types present in PDACs. CCR7 expression was significantly downregulated in CD8+ T cells in Arm C whereas CCL5, a T cell agonist cytokine, and LCP2, a TCR signaling activator and T cell receptor which is also required for integrin signaling, were significantly upregulated in CD8+ T cells in Arm C. The increased integrin ligand signaling via ICAM1 and LCP2 in Arm C is also associated with changes in CD8+ T cell motility observed from the differential expression analysis. Conclusions: Analysis of combination GVAX, PD-1 inhibition and CD137 agonist therapy demonstrated changes in multiple immune cell proportions and their functional pathways. These data provide new evidence that PDACs can become T cell rich and respond to combination immunotherapies. Citation Format: Joseph A. Tandurella, Jacob T. Mitchell, Janelle M. Montagne, Eric Christenson, Qingfeng Zhu, Ludmilla V. Danilova, Alexander V. Favorov, Won J. Ho, Luciane T. Kagohara, Melanie Loth, Su Jin Lim, Rui Zheng, Jessica Gai, Sarah Mitchell, Dimitrios N. Sidiropoulos, Wenpin Hou, Yao Xu, Hao Wang, Jacquelyn W. Zimmerman, Srinivasan Yegnasubramanian, Robert Anders, Elizabeth M. Jaffee, Lei Zheng, Elana J. Fertig. Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3241.

oncology
Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor

S Ji,J Li,L Chang,C Zhao,R Jia,Z Tan,R Liu,Y Zhang,Y Li,G Yin,Y Guan,X Xia,X Yi,J Xu

DOI: https://doi.org/10.1007/s12094-021-02562-4

Abstract:Background: Identifying valid biomarkers for patient selection impressively promotes the success of anti-PD-1 therapy. However, the unmet need for biomarkers in gastrointestinal (GI) cancers remains significant. We aimed to explore the predictive value of the circulating T-cell receptor (TCR) repertoire for clinical outcomes in GI cancers who received anti-PD-1 therapy. Methods: 137 pre- and 79 post-treated peripheral blood samples were included. The TCR repertoire was evaluated by sequencing of complementarity-determining region 3 (CDR3) in the TRB gene. The Shannon index was used to measure the diversity of the TCR repertoire, and Morisita's overlap index was used to determine TCR repertoire similarities between pre- and post-treated samples. Results: Among all enrolled patients, 76 received anti-PD-1 monotherapy and 61 received anti-PD-1 combination therapy. In the anti-PD-1 monotherapy cohort, patients with higher baseline TCR diversity exhibited a significantly higher disease control rate (77.8% vs. 47.2%; hazard ratio [HR] 3.92; 95% confidence interval [CI] 1.14-13.48; P = 0.030) and a longer progression-free survival (PFS) (median: 6.47 months vs. 2.77 months; HR 2.10; 95% CI 1.16-3.79; P = 0.014) and overall survival (OS) (median: NA vs. 8.97 months; HR 3.53; 95% CI 1.49-8.38; P = 0.004) than those with lower diversity. Moreover, patients with a higher TCR repertoire similarity still showed a superior PFS (4.43 months vs. 1.84 months; HR 13.98; 95% CI 4.37-44.68; P < 0.001) and OS (13.40 months vs. 6.12 months; HR 2.93; 95% CI 1.22-7.03; P = 0.016) even in the cohort with lower baseline diversity. However, neither biomarker showed predictive value in the anti-PD-1 combination therapy cohort. Interestingly, the combination of TCR diversity and PD-L1 expression can facilitate patient stratification in a pooled cohort. Conclusion: The circulating TCR repertoire can serve as a predictor of clinical outcomes in anti-PD-1 therapy in GI cancers.
Abstract 5261: Immunologic signatures of peripheral blood cells in patients with advanced pancreatic cancer under lenvatinib-pembrolizumab maintenance therapy

Vincent Chung,Ferdynand Kos,Edwin Manual,Shannon Dempsey,Don J. Diamond

DOI: https://doi.org/10.1158/1538-7445.am2024-5261

IF: 11.2

2024-03-26

Cancer Research

Abstract:Background: The treatment of pancreatic cancer is limited by chemotherapy toxicities which impacts quality of life. This is a phase 2 clinical trial of lenvatinib and pembrolizumab as maintenance therapy in patients with advanced pancreatic cancer. We observed preclinical activity of this combination in pancreatic mouse models. We hypothesize that this combination may address unmet needs to minimize toxicities associated with standard treatments, stimulate anti-tumor T cell immunity, and improve the progression free and overall survival. Exploratory studies aim to characterize immune-related systemic changes in peripheral blood over the course of therapy and to identify global changes in expression of tumor-related genes in needle biopsy samples of liver metastatic lesions. Methods: Multiplex gene expression analysis of unsorted peripheral blood mononuclear cells (PBMC) was performed using PanCancer Immune Profiling Panel on NanoString nCounter platform. PBMC samples from pre- through week 32 of treatment were assessed for differential expression of 730 immune profiling genes defining T cell functions and associated immune categories. Results: PBMC immune profiling from 4/5 patients show a distinctive pattern of increased activation of T cells during the first 9 weeks of treatment followed by a sharp inhibition starting at weeks 9-12 after 3-4 cycles of treatment (CD3E, CD247, LCK, TBX1, TCF7, STAT4, IL2RG). Subsequent upregulation of macrophage-derived scavenger, inflammatory, and immunosuppressive gene expression patterns continued for the remainder of treatment (CD14, MSR1, MARCO, CD68, TGFB1, IL10RA). The median PFS of first 10 patients was 21.5 (9-32) weeks. Conclusions: Immunotherapy resistance may be related to rapidly developing terminal differentiation and unresponsiveness of T cells in parallel with upregulation of macrophage-derived inflammatory and immunosuppressive processes. Studies are on-going to prevent inhibition of the T-cells. Citation Format: Vincent Chung, Ferdynand Kos, Edwin Manual, Shannon Dempsey, Don J. Diamond. Immunologic signatures of peripheral blood cells in patients with advanced pancreatic cancer under lenvatinib-pembrolizumab maintenance therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5261.

oncology
Abstract 2847: Simultaneous TCR and transcriptomic sequencing of single Tcells defines biological subtypes in pancreatic cancer for adoptive Tcell therapy

Aislyn Schalck,Donastas Sakellariou-Thompson,Marie-Andrée Forget,Emi Sei,Tara Hughes,Shanshan Bai,Min Hu,Tapsi Kumar,Mark Hurd,Matthew Katz,Chine-Wei Tzeng,Shubham Pant,Milind Javle,Anirban Maitra,Cara Haymaker,Michael Kim,Nicholas Navin,Chantale Bernatchez

DOI: https://doi.org/10.1158/1538-7445.am2022-2847

IF: 11.2

2022-06-17

Cancer Research

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal tumor-type with very few effective treatment strategies. Attempts to improve outcomes using immune checkpoint blockade therapy have also failed, likely because the overall Tcell infiltration in this tumor-type is low. Despite this, the presence of CD3+CD8+ tumor-infiltrating lymphocytes (TIL) in PDAC is associated with improved survival outcomes, suggesting that other immune-based strategies could be more successful. Here, we examine ex vivo tumor-infiltrating Tcell expansion for adoptive Tcell therapy (ACT) as a potential strategy for treating PDAC. The focus of this study is to understand the transcriptional states of Tcells in the pancreas and PDACs and how they change with ex vivo expansion and re-infusion into patients as treatment strategy. We have performed both single cell transcriptome and TCR sequencing (scRNA-TCRseq) on 54,579 Tcells from 8 human PDAC samples and the ex vivo grown TIL from a subset of 6 patients and found 13 purported substates. Through TCR tracking of the Tcell clonotypes, we find that the expansion protocol is able to expand Tcells found in many different Tcell states in the primary tumor. Furthermore, we compared our thirteen tumor-infiltrating substates with 41,935 Tcells from two other independent single cell studies across 71 samples, and confirmed our substates to be present across all datasets. Citation Format: Aislyn Schalck, Donastas Sakellariou-Thompson, Marie-Andrée Forget, Emi Sei, Tara Hughes, Shanshan Bai, Min Hu, Tapsi Kumar, Mark Hurd, Matthew Katz, Chine-Wei Tzeng, Shubham Pant, Milind Javle, Anirban Maitra, Cara Haymaker, Michael Kim, Nicholas Navin, Chantale Bernatchez. Simultaneous TCR and transcriptomic sequencing of single Tcells defines biological subtypes in pancreatic cancer for adoptive Tcell therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2847.

oncology
Abstract 6397: Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma

Joanna Baginska,Jiajia Chen,Giuseppe Tarantino,Anita Giobbie-Hurder,Jason L. Weirather,Mariano Severgnini,Michael Manos,Kelly Burke,Janice D. Russell,Martha Brainard,Elizabeth Gabriel,Ryan Brennick,Matthew Nazzaro,Emma Hathaway,Marta Holovatska,Claire Manuszak,Srinika Ranashinge,David Liu,F. Stephen Hodi

DOI: https://doi.org/10.1158/1538-7445.am2024-6397

IF: 11.2

2024-03-28

Cancer Research

Abstract:Background:aCTLA-4 and aPD-1 combination therapy has significantly improved clinical outcomes in patients with metastatic melanoma, with 50%-60% of patients responding to treatment, but predictors of response and treatment induced immunological effects are poorly characterized. Identifying circulating immune populations as biomarkers could reveal crucial insights into the mechanisms driving treatment success. Methods:Using unbiased single-cell profiling (with cytometry by Time-Of-Flight, CyTOF), we characterized the systemic immune compartments of over 250 peripheral blood mononuclear samples from 89 patients with advanced melanoma before and during combination therapy. We evaluated the association between circulating immune populations and clinical outcome using nonparametric Mann-Whitney tests, and investigated the prognostic values of these features using survival analysis. Additionally, we assessed treatment-induced immunological effects, providing insights into the dynamic changes within the immune system during therapy. Results:We characterized circulating T cells, NK cells, B cells, and monocytes from peripheral blood. Following combination therapy, there was a shift from naïve and central memory T cells to effector populations in both CD4+ and CD8+ T cells compartments. There was also a broad activation observed in both adaptive and innate populations, characterized by an elevation of multiple co-stimulatory and co-inhibitory molecules. Lower CD8+ NK cell populations prior to combination therapy were predictive of durable clinical benefit (DCB). Pre-treatment measurements of Tregs were not predictive of outcome, but higher Tregs one month after starting therapy, as well as increases of Tregs from pre to post treatment, predicted better progression free survival (PFS) and overall survival (OS). Starting from early on treatment, higher "exhausted-like" CD8+ T cells, characterized by positive expression of at least two co-inhibitory markers, is associated with resistance. Conclusions:aCTLA-4 and aPD-1 combination therapy led to a longitudinal shift from naïve and central memory to effector phenotypes in T cells, along with a broad activation in both adaptive and innate populations. Within innate immune compartment, favorable clinical outcome was associated with lower CD8+ NK cells, capable of regulating proliferation and activation of CD4+ T cells. Interestingly, one month after the start of the therapy, the increase in Tregs and a decrease in 'exhausted-like' CD8+ T populations are associated with a better response. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in future. Citation Format: Joanna Baginska, Jiajia Chen, Giuseppe Tarantino, Anita Giobbie-Hurder, Jason L. Weirather, Mariano Severgnini, Michael Manos, Kelly Burke, Janice D. Russell, Martha Brainard, Elizabeth Gabriel, Ryan Brennick, Matthew Nazzaro, Emma Hathaway, Marta Holovatska, Claire Manuszak, Srinika Ranashinge, David Liu, F. Stephen Hodi. Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6397.

oncology
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

Keyu Li,Jessica Gai,Qingfeng Zhu,Su Jin Lim,Tao Xia,Guanglan Mo,Janelle Montagne,Melissa Lyman,Benedict Kinny-Köster,Tengyi Zhang,Linda Chen,Thatcher Heumann,Rose Parkinson,Jin He,Arsen Osipov,Hao Wang,Lei Zheng,Joseph A. Tandurella,Dwayne L. Thomas,Jacob T. Mitchell,Ludmila V. Danilova,Jacquelyn W. Zimmerman,Alex B. Blair,Jennifer N. Durham,Amol K. Narang,Robert A. Anders,Christopher L. Wolfgang,Daniel A. Laheru,Elizabeth D. Thompson,Elana J. Fertig,Elizabeth M. Jaffee

DOI: https://doi.org/10.1016/j.ccell.2022.10.001

IF: 50.3

2022-11-15

Cancer Cell

Abstract:Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy necessitates optimization and maintenance of activated effector T cells (Teff). We prospectively collected and applied multi-omic analyses to paired pre- and post-treatment PDAC specimens collected in a platform neoadjuvant study of granulocyte-macrophage colony-stimulating factor-secreting allogeneic PDAC vaccine (GVAX) vaccine ± nivolumab (anti-programmed cell death protein 1 [PD-1]) to uncover sensitivity and resistance mechanisms. We show that GVAX-induced tertiary lymphoid aggregates become immune-regulatory sites in response to GVAX + nivolumab. Higher densities of tumor-associated neutrophils (TANs) following GVAX + nivolumab portend poorer overall survival (OS). Increased T cells expressing CD137 associated with cytotoxic Teff signatures and correlated with increased OS. Bulk and single-cell RNA sequencing found that nivolumab alters CD4 + T cell chemotaxis signaling in association with CD11b + neutrophil degranulation, and CD8 + T cell expression of CD137 was required for optimal T cell activation. These findings provide insights into PD-1-regulated immune pathways in PDAC that should inform more effective therapeutic combinations that include TAN regulators and T cell activators. Introduction Immune checkpoint inhibitors (ICIs) are a major breakthrough in cancer therapeutics; however, less than 20% of all cancer patients respond to ICIs as single agents (Osipov et al., 2019 Osipov A. Murphy A. Zheng L. From immune checkpoints to vaccines: the past, present and future of cancer immunotherapy. Adv. Cancer Res. 2019; 143 : 63-144 Crossref PubMed Scopus (30) Google Scholar ; Sharma and Allison, 2015 Sharma P. Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161 : 205-214 Full Text Full Text PDF PubMed Scopus (1454) Google Scholar ). Pancreatic ductal adenocarcinomas (PDACs) are among the prototypic, immunogenically "cold" tumors because they lack natural infiltration of effector T cells (Teffs), the cells that respond to ICIs (Ho et al., 2020 Ho W.J. Jaffee E.M. Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 2020; 17 : 527-540 Crossref PubMed Scopus (284) Google Scholar ). To convert PDACs into ICI-responsive tumors, effective immunotherapy strategies are required to (1) increase antigenicity, (2) enhance Teff function, and (3) overcome T cell excluding and immunosuppressive signals in the tumor microenvironment (TME) (Johnson et al., 2017 Johnson B.A. Yarchoan M. Lee V. Laheru D.A. Jaffee E.M. Strategies for increasing pancreatic tumor immunogenicity. Clin. Cancer Res. 2017; 23 : 1656-1669 Crossref PubMed Scopus (99) Google Scholar ; Popovic et al., 2018 Popovic A. Jaffee E.M. Zaidi N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J. Clin. Invest. 2018; 128 : 3209-3218 Crossr -Abstract Truncated-

oncology,cell biology
Circulating Regulatory T Cell Subsets Predict Overall Survival of Patients with Unresectable Pancreatic Cancer.

Chen Liu,He Cheng,Guopei Luo,Yu Lu,Kaizhou Jin,Meng Guo,Quanxing Ni,Xianjun Yu

DOI: https://doi.org/10.3892/ijo.2017.4032

2017-01-01

International Journal of Oncology

Abstract:Most patients with pancreatic ductal adenocarcinoma (PDAC) have unresectable cancers with a dismal prognosis, in which cohort chemotherapy is the primary treatment. T cell immune adaption is critical for tumor immune escape and prognosis of this disease. The present study aimed to determine the correlation between peripheral T cell subset distribution in patients with unresectable PDAC and their response to chemotherapy. Two hundred and twelve patients with unresectable PDAC were included whose blood samples were collected for analysis of T cell subsets, including CD3+, CD4+, CD8+, CD8+CD28+ and CD4+CD25+CD127 T cells by flow cytometry before and after gemcitabine-based chemotherapy. Enzyme-linked immunosorbent assay was used to detect the expression levels of tumor growth factor (TGF)-β1, interleukin (IL)-6 and IL-17A in the patients before and after chemotherapy. Univariate and multivariate analyses found that an initial CD4/CD8 ratio or T regulatory (Treg) cell level before any treatment was associated with the prognosis of unresectable PDAC. After two cycles of chemotherapy, there was no significant change in percentages of T cell subsets, except elevation to a higher level of CD3+ T cells. Decreased Tregs or CD4/CD8 ratio after two cycles of chemotherapy predicts a longer overall survival (OS). Levels of Tregs in stable disease (SD) and partial remission (PR) cases significantly decreased after chemotherapy, but increased in progressive disease (PD) patients. There was no correlation between Tregs and the expression level of either TGF-β1 or IL-6. IL-17A expression was elevated in Treg-decreased patients, whereas IL-17A was reduced in Treg-increased patients after chemotherapy. The circulating signature of T cell subsets can predict OS and chemotherapeutic response in patients with unresectable PDAC, and may be attributable to the plasticity of T cell subsets.
T Cell Receptor Β‐chain Repertoire Analysis of Tumor‐infiltrating Lymphocytes in Pancreatic Cancer

Can Cui,Xiuyun Tian,Jianhui Wu,Chaoting Zhang,Qin Tan,Xiaoya Guan,Bin Dong,Min Zhao,Zheming Lu,Chunyi Hao

DOI: https://doi.org/10.1111/cas.13877

IF: 5.7

2018-01-01

Cancer Science

Abstract:Pancreatic cancer is lethal due to lack of perceptible symptoms and effective treatment methods. Immunotherapy may provide promising therapeutic choices for malignant tumors like pancreatic cancer. Tumor‐infiltrating lymphocytes (TIL) in tumor mesenchyme could recognize peptide antigens presented on the surface of tumor cells. The present study aimed to test the relationship between the T cell receptor (TCR) β repertoire of the tumor and peripheral blood, and also to investigate the intra‐tumor spatial heterogeneity of the TCR β repertoire in pancreatic cancer. To the best of our knowledge, this is the first study to evaluate the clonal composition of TCR β repertoire in TIL across the spatial extent of pancreatic cancer. In this study, we studied 5 patients who were diagnosed with primary pancreatic cancer. Ultra‐deep sequencing was used to assess the rearrangement of the TCR β‐chain (TCR β) gene. HE staining and immunohistochemistry of CD3, CD4, CD8 and HLA class I were used to show histopathology and immune conditions macroscopically. TIL repertoire showed that different regions of the same tumor showed a greater number of repertoire overlaps between each other than between peripheral blood, which suggested that T cell clones in pancreatic cancer might be quite different from those in peripheral blood. In contrast, intra‐tumoral TCR β repertoires were spatially homogeneous between different regions of a single tumor tissue. Based on these results, we speculated that the cellular adaptive immune response in pancreatic cancer was spatially homogeneous; this may pave the way for immunotherapy for the treatment of pancreatic cancer patients.
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy

Mohamed Shanavas,Soi-Cheng Law,Mark Hertzberg,Rodney J Hicks,John F Seymour,Zhixiu Li,Lilia Merida de Long,Karthik Nath,Muhammed B Sabdia,Jay Gunawardana,Maher K Gandhi,Colm Keane

DOI: https://doi.org/10.1002/cti2.1351

2021-10-27

Abstract:Objectives: A diverse intratumoral T-cell receptor (TCR) repertoire is associated with improved survival in diffuse large B-cell lymphoma (DLBCL) treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. We explored the impact of intratumoral TCR repertoire on interim PET (iPET) done after four cycles of R-CHOP, the relationships between intratumoral and circulating repertoire, and the phenotypes of expanded clonotypes. Methods: We sequenced the third complementarity-determining region of TCRβ in tumor samples, blood at pre-therapy and after four cycles of R-CHOP in 35 patients enrolled in ALLGNHL21 trial in high-risk DLBCL. We correlated the TCR diversity metrics with iPET status, gene expression profiles and HLA-class I genotypes. We then sequenced the FACS-sorted peripheral blood T cells in six patients, and pentamer-sorted EBV-specific CD8+ T cells in one patient from this cohort. Results: Compared with iPET- patients, the intratumoral TCR repertoire in iPET+ patients was characterised by higher cumulative frequency of abundant clonotypes and higher productive clonality. There was a variable overlap between circulating and intratumoral repertoires, with the dominant intratumoral clonotypes more likely to be detected in the blood. The majority of shared clonotypes were CD8+ PD-1HI T cells, and CD8+ T cells had the largest clonal expansions in tumor and blood. In a patient with EBV+ DLBCL, EBV-specific intratumoral clonotypes were trackable in the blood. Conclusion: This study demonstrates that clonally expanded intratumoral TCR repertoires are associated with iPET+ and that the blood can be used to track tumor-associated antigen-specific clonotypes. These findings assist the rationale design and therapeutic monitoring of immunotherapeutic strategies in DLBCL.
Abstract C026: Single-cell multi-omics in pancreatic cancer reveals differential immune evasion mechanisms between prognostic groups

Shivan Sivakumar,Ashwin Jainarayanan,Edward Arbe-Barnes,Enas Abu-Shah,Rachael Bashford-Rogers

DOI: https://doi.org/10.1158/1538-7445.panca2023-c026

IF: 11.2

2024-01-18

Cancer Research

Abstract:Pancreatic cancer has the worst survival of any human cancer with a 5 year survival of less than 10% with minimal treatment options. We have previously made the observation that patients with a T cell infiltrate in their primary tumor have a better prognosis then those that do not. To understand the nature of the immune infiltrate, we have in 12 patients performed 10X sequencing on CD45 cells from the tumor as well as single cell TCR-seq, BCR-seq and cite-seq and have performed the same experiment on the matching PBMCs. We have generated a dataset of approximately 185000 cells with half coming from the tumor. This unravels a complex immune infiltrate with the predominant immune cell types consisting of T cells. Our data shows that within the tumor infiltrate, patients either have high or low myeloid infiltration. We see a highly active Treg population that has multiple checkpoints activated. Using TCR data, we saw the biggest clonal expansions in CD8 EM, CD8 senescent cells and Tregs. Circulating TIL CD4 T cells are dominated by activated Tregs, Tfh, and Th2 and circulating TIL CD8 T cells are dominated by CD8 EM T cells. Our work identifies multiple novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma. Citation Format: Shivan Sivakumar, Ashwin Jainarayanan, Edward Arbe-Barnes, Enas Abu-Shah, Rachael Bashford-Rogers. Single-cell multi-omics in pancreatic cancer reveals differential immune evasion mechanisms between prognostic groups [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C026.

oncology
Clinical Significance of Peripheral T-cell Receptor Repertoire Profiling and Individualized Nomograms in Patients with Gastrointestinal Cancer Treated with Anti-Programmed Death 1 Antibody.

Jing Wu,Yiyi Yu,Shilong Zhang,Pengfei Zhang,Shan Yu,Wei Li,Yan Wang,Qian Li,Binbin Lu,Limeng Chen,Chonglin Luo,Haixiang Peng,Tianshu Liu,Yuehong Cui

DOI: https://doi.org/10.21037/tgh-23-61

2024-01-01

Translational Gastroenterology and Hepatology

Abstract:Background:Immune checkpoint inhibitors (ICIs) have significant clinical benefit for a subset of patients with gastrointestinal cancers (GICs) including esophageal cancer, gastric cancer and colorectal cancer. However, it is difficult to predict which patients will respond favorably to immune checkpoint blockade therapy. Thus, this study was initiated to determine if peripheral T-cell receptor (TCR) repertoire profiling could predict the clinical efficacy of anti-programmed death 1 (PD-1) treatment.Methods:Blood samples from 31 patients with GICs were collected before anti-PD-1 antibody treatment initiation. The clinical significance of the combinatorial diversity evenness of the TCR repertoire [the diversity evenness 50 (DE50), with high values corresponding to less clonality and higher TCR diversity] from peripheral blood mononuclear cells (PBMCs) was evaluated in all the enrolled patients. A highly predictive nomogram was set up based on peripheral TCR repertoire profiling. The performance of the nomogram was assessed by receiver operating characteristic (ROC) curve, concordance index (C-index), and calibration curves, and decision curve analysis (DCA) was used to assess its clinical applicability.Results:Compared to non-responders [progression disease (PD)], the DE50 scores were significantly higher in responders [stable disease (SD) and partial response (PR)] (P=0.018). Patients with a high DE50 score showed better progression-free survival (PFS) than those with a low DE50 score (P=0.0022). The multivariable Cox regression demonstrated that high DE50 and low platelet-lymphocyte ratio (PLR) were significant independent predictors for better PFS when treated with anti-PD-1 antibody. Furthermore, a highly predictive nomogram was set up based on peripheral TCR repertoire profiling. The area under the curves (AUCs) of this system at 3-, 6- and 12-month PFS reached 0.825, 0.802, and 0.954, respectively. The nomogram had a C-index of 0.768 [95% confidence interval (CI): 0.658-0.879]. Meanwhile, the calibration curves also demonstrated the reliability and stability of the model.Conclusions:High DE50 scores were predictive of a favorable response and longer PFS to anti-PD-1 treatment in GIC patients. The nomogram based on TCR repertoire profiling was a reliable and practical tool, which could provide risk assessment and clinical decision-making for individualized treatment of patients.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Luis A. Rojas,Zachary Sethna,Kevin C. Soares,Cristina Olcese,Nan Pang,Erin Patterson,Jayon Lihm,Nicholas Ceglia,Pablo Guasp,Alexander Chu,Rebecca Yu,Adrienne Kaya Chandra,Theresa Waters,Jennifer Ruan,Masataka Amisaki,Abderezak Zebboudj,Zagaa Odgerel,George Payne,Evelyna Derhovanessian,Felicitas Müller,Ina Rhee,Mahesh Yadav,Anton Dobrin,Michel Sadelain,Marta Łuksza,Noah Cohen,Laura Tang,Olca Basturk,Mithat Gönen,Seth Katz,Richard Kinh Do,Andrew S. Epstein,Parisa Momtaz,Wungki Park,Ryan Sugarman,Anna M. Varghese,Elizabeth Won,Avni Desai,Alice C. Wei,Michael I. D’Angelica,T. Peter Kingham,Ira Mellman,Taha Merghoub,Jedd D. Wolchok,Ugur Sahin,Özlem Türeci,Benjamin D. Greenbaum,William R. Jarnagin,Jeffrey Drebin,Eileen M. O’Reilly,Vinod P. Balachandran

DOI: https://doi.org/10.1038/s41586-023-06063-y

IF: 64.8

2023-05-10

Nature

Abstract:Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8 + T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence.

multidisciplinary sciences
Peripheral T-cell receptor repertoire dynamics in small cell lung cancer

Meridith L. Balbach,Margaret L. Axelrod,Justin M. Balko,Armand Bankhead,Tristan Shaffer,Lee Lim,Jiannan Guo,Jennifer Hernandez,Mark Li,Wade T. Iams

DOI: https://doi.org/10.21037/tlcr-22-666

2023-02-24

Translational Lung Cancer Research

Abstract:Background: Identifying a circulating biomarker predictive of immune checkpoint inhibitor (ICI) benefit in patients with small cell lung cancer (SCLC) remains an unmet need. Characteristics of peripheral and intratumoral T-cell receptor (TCR) repertoires have been shown to predict clinical outcomes in non-small cell lung cancer (NSCLC). Recognizing a knowledge gap, we sought to characterize circulating TCR repertoires and their relationship with clinical outcomes in SCLC.Methods: SCLC patients with limited (n=4) and extensive (n=10) stage disease were prospectively enrolled for blood collection and chart review. Targeted next-generation sequencing of TCR beta and alpha chains of peripheral blood samples was performed. Unique TCR clonotypes were defined by identical CDR3, V gene, and J gene nucleotide sequences of the beta chain and subsequently used to calculate TCR diversity indices.Results: Patients with stable versus progressive and limited versus extensive stage disease did not demonstrate significant differences in V gene usage. Kaplan-Meier curve and log-rank analysis did not identify a statistical difference in progression-free survival (PFS) (P=0.900) or overall survival (OS) (P=0.200) between high and low on-treatment TCR diversity groups, although the high diversity group exhibited a trend toward increased OS.Conclusions: We report the second study investigating peripheral TCR repertoire diversity in SCLC. With a limited sample size, no statistically significant associations between peripheral TCR diversity and clinical outcomes were observed, though further study is warranted.

oncology,respiratory system
Abstract PR-06: Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

Pablo Guasp,Zachary Sethna,Charlotte Reiche,Martina Milighetti,Nicholas Ceglia,Erin Patterson,Nan Pang,George Payne,Ohmoto Akihiro,Luis A Rojas,Masataka Amisaki,Abderezak Zebboudj,Emmanuel Bruno,Linsey Zhang,Zagaa Odgerel,Charlotte Cheng,Evelyna Derhovanessian,Luisa Manning,Felicitas Müller,Ina Rhee,Mahesh Yadav,Mithat Gönen,Olca Basturk,Andre S Epstein,Parisa Momtaz,Wungki Park,Ryan Sugarman,Anna M Varghese,Elizabeth Won,Avni Desai,Alice C Wei,Michael I D'Angelica,Peter Kingham,Kevin C Soares,William R Jarnagin,Jeffrey Drevin,Eileen M O'Reilly,Ira Mellman,Ugur Sahin,Özlem Türeci,Benjamin D Greenbaum,Vinod P Balachandran

DOI: https://doi.org/10.1158/2326-6074.tumimm24-pr-06

IF: 10.1

2024-10-19

Cancer Immunology Research

Abstract:Background: A fundamental barrier for cancer vaccines is the challenge to generate long-lived functional T cells specific to tumor antigens. Here, in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations, we discover that mRNA vaccines against mutation-derived neoantigens may solve this challenge. We recently reported (Rojas et al., Nature 2023) 1.5-yr median follow-up data (phase-I, NCT04161755) of sequential adjuvant atezolizumab (αPD-L1), autogene cevumeran (individualized neoantigen vaccine based on uridine mRNA-lipoplex nanoparticles), and mFOLFIRINOX in 16 surgically resected PDAC patients. Autogene cevumeran induced high-magnitude neoantigen-specific T cells in 8 patients (responders). Responders had prolonged recurrence-free survival (RFS, not reached) versus non-responders (no vaccine-induced T cells, RFS 13.4 mo; HR=0.08; P=0.003). Here, we track if vaccine-induced T cells persist, function, and correlate with improved RFS at 3-yr median follow- up. Methods: In responders, we analyzed T cell clones before vaccination in tumors, tumor-draining lymphatic and adjacent tissues (24 samples, 212K clones), and sequentially up to 3 yr after vaccination in blood (q1-2 wk surgery to vaccination; q3 mo post-vaccination; 124 samples, 26 timepoints, 5M clones) with TCRVβ sequencing. We used our custom mathematical strategy (CloneTrack) to measure persistence and estimate lifespan of vaccine-induced clones. To assess long-term T cell function, we rechallenged peripheral T cells 1.8-2.6 yr post-vaccination (memory phase) with neopeptides in vitro. In 16 vaccinated patients, we analyzed RFS. Results: Autogene cevumeran induced 79 CD8+ T cell clones in the blood with an estimated median lifespan of 5.5 yr (range 1.3-70.2). Autogene cevumeran primed multiple CD8+ T cell clones per patient (median 8, range 2-28); 98% of clones were absent in pre- vaccination host tissues to suggest vaccines prime clones de novo. Of primed clones, 85% persisted into the memory phase at high frequencies (median 0.1% of all blood T cells). Despite post-vaccination chemotherapy, memory phase CD8+ T cells produced IFNγ, TNFα, and degranulated upon neoantigen rechallenge in 6 of 8 responders. At 3-yr median follow-up (range 2.3-3.8), responders continued to exhibit prolonged RFS (median RFS not reached) compared to non-responders (median RFS 13.4 mo; HR=0.14; 95% CI 0.03-0.6; P=0.007). Two responders recurred and evidenced fewer aggregate vaccine-induced T cells vs. responders who did not recur. Conclusion: In PDAC, autogene cevumeran induces polyfunctional CD8+ T effector cells of significant longevity, substantial magnitude, and durable function that correlate with delayed recurrence at sustained follow-up. mRNA may thus fulfill a pivotal requisite for effective cancer vaccines. Citation Format: Pablo Guasp, Zachary Sethna, Charlotte Reiche, Martina Milighetti, Nicholas Ceglia, Erin Patterson, Nan Pang, George Payne, Ohmoto Akihiro, Luis A Rojas, Masataka Amisaki, Abderezak Zebboudj, Emmanuel Bruno, Linsey Zhang, Zagaa Odgerel, Charlotte Cheng, Evelyna Derhovanessian, Luisa Manning, Felicitas Müller, Ina Rhee, Mahesh Yadav, Mithat Gönen, Olca Basturk, Andre S Epstein, Parisa Momtaz, Wungki Park, Ryan Sugarman, Anna M Varghese, Elizabeth Won, Avni Desai, Alice C Wei, Michael I D'Angelica, Peter Kingham, Kevin C Soares, William R Jarnagin, Jeffrey Drevin, Eileen M O'Reilly, Ira Mellman, Ugur Sahin, Özlem Türeci, Benjamin D Greenbaum, Vinod P Balachandran. Personalized RNA neoantigen vaccines induce long-lived CD8T effector cells in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-06.

oncology,immunology
PROGNOSTIC AND PREDICTIVE VALUE OF PRE-TREATMENT T-CELL RECEPTORS (TCR) REPERTOIRE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH SINGLE AGENT IMMUNOTHERAPY

E. Gray,A. Abed

Abstract:Background TCR repertoire plays a key role on the orchestration of the immune response. In particular, reduced pre-treatment Shannon diversity, increase clonality and increase convergence of TCRs have been suggested to reflect clonal expansion of antigen-specific T-cells in the tumour microenvir-onment. These are thought to be correlated with better response rate, improved progression free survival (PFS) and overall survival (OS). Here we aim to explore the above TCR repertoire features in peripheral blood of NSCLC patients (with PDL1 (cid:1) 50%) treated with single agent pembrolizumab in the first line setting; and correlate them with overall response rate (ORR), PFS and OS. Methods We prospectively collected baseline blood from 48 NSCLC patients treated with first line pembrolizumab. High quality DNA was extracted from white blood cells and used for TCR sequencing using the Oncomine TCR Beta-SR Assay (Thermo Fisher). TCR clonality and convergence were calculated for each individual and correlated with survival using Kaplan-Meier curves and survival statistics. Multivariate analysis was carried out controlling for other variable that may influence the association of TCR repertoire and outcomes such as age, sex, ECOG, smoking status and pre-treatment neutrophil to lymphocyte ratio (NLR). Results Our data matured for 29 patients only with a follow-up of at least 6 months. We observed a trend towards increased pre-treatment TCR clonality in patients with objec-tive response to pembrolizumab and statistically significant reduced Shannon diversity (P = 0.042). Convergence did not seem to affect ORR in our cohort. Moreover, there was a significantly

Medicine
Abstract A010: Tumor-reactive T cell clonal dynamics across treatment time points drive resistance and progression to frontline chemoimmunotherapy in advanced gastric cancer

Samuel J. Wright,Minae An,Byung Hoon Min,You Jeong Heo,Milan Parikh,Lynn Bi,Hyuk Lee,Taejun Kim,Song-Yi Lee,Jeonghyeon Moon,Matthew R. Strickland,Woong Yang Park,Won Ki Kang,Kyoung-Mee Kim,Seung Tae Kim,Ryan J. Park,Arnav Mehta,Samuel Klempner,Jeeyun Lee

DOI: https://doi.org/10.1158/2326-6074.tumimm24-a010

IF: 10.1

2024-10-19

Cancer Immunology Research

Abstract:Adding aPD1 to 5-FU/platinum in advanced gastroesophageal adenocarcinomas (GEA) has yielded modest and heterogeneous results. Understanding cooperativity between these two treatment modalities will inform novel combination treatments for GEA. Towards this end, we conducted a trial (n = 47) sequentially adding pembrolizumab to 5-FU/platinum in previously untreated advanced GEA. Using serial biopsy of the primary tumor at baseline, after one cycle of 5-FU/platinum, and after the addition of pembrolizumab we profiled 66,816 tumor-resident T cells with matched single-cell RNA-seq and single-cell TCR-seq. Stratifying patients into slow- (> 6 months) and fast-progressing (< 6 months) groups based on progression-free survival allowed us to quantify clonal and transcriptional differences in T cell subpopulations across three time points. We annotated CD4 and CD8 T cell phenotypes according to canonical marker genes and found evidence of 17 different subpopulations along various stages of memory and exhaustion trajectories. We found differences in the abundance of T cell subtypes between slow- and fast-progressors at various treatment time points. T cells with exhausted phenotypes were more abundant in slow progressors in the post-chemo and post-immunotherapy time points. Additionally, we found changes in phenotypic abundances between clones shared between time points. For example, clonotypes that were predominantly of the progenitor exhausted phenotype pre-immunotherapy had a notable proportion of shared post-ICB clones exhibiting an activated phenotype. Previous studies have highlighted exhausted T cells as having important roles in maintaining tumor immunity as these tend to be subject to chronic antigen stimulation due to their specificity to tumor antigen. For this reason, we identified tumor-reactive T cell clonotypes among our data using literature-defined proxies such as CXCL13 expression, exhaustion status and degree of post-therapeutic clonal expansion, in addition to transcription signature-based predictions using machine learning tools such as predicTCR and TRTpred. We found that tumor-reactive T cell clonotypes tended to be present in slow progressors across time points. CXCL13 had variable patterns of upregulation and downregulation depending on whether a particular tumor-reactive clonotype was expanding or contracting at a specific treatment time point. Moreover, we quantified whether these tumor reactive clonotypes shared clones with non-exhausted T cell subsets prior to treatment or whether they were newly present in the tumor microenvironment (TME) post-treatment to determine the relative contributions of phenotypic transition and peripheral replenishment to tumor reactive T cells in the gastric cancer tumor microenvironment. Our data provide an invaluable resource to understand T cell behavior in the context of chemoimmunotherapy and propose strategies to drive anti-tumor immunity to expand the portion of patients benefiting from immunotherapy approaches. Citation Format: Samuel J. Wright, Minae An, Byung Hoon Min, You Jeong Heo, Milan Parikh, Lynn Bi, Hyuk Lee, Taejun Kim, Song-Yi Lee, Jeonghyeon Moon, Matthew R. Strickland, Woong Yang Park, Won Ki Kang, Kyoung-Mee Kim, Seung Tae Kim, Ryan J. Park, Arnav Mehta, Samuel Klempner, Jeeyun Lee. Tumor-reactive T cell clonal dynamics across treatment time points drive resistance and progression to frontline chemoimmunotherapy in advanced gastric cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A010.

oncology,immunology
Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

Erik S Knudsen,Paris Vail,Uthra Balaji,Hoai Ngo,Ihab W Botros,Vladimir Makarov,Nadeem Riaz,Vinod Balachandran,Steven Leach,Debrah M Thompson,Timothy A Chan,Agnieszka K Witkiewicz

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0162

2017-08-01

Abstract:Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with an immunosuppressive milieu that supports immune system evasion and disease progression. Here, we interrogated genetic, stromal, and immunologic features of PDAC to delineate impact on prognosis and means to more effectively employ immunotherapy.Experimental Design: A cohort of 109 PDAC cases annotated for overall survival was utilized as a primary discovery cohort. Gene expression analysis defined immunologic subtypes of PDAC that were confirmed in the Cancer Genome Atlas dataset. Stromal and metabolic characteristics of PDAC cases were evaluated by histologic analysis and immunostaining. Enumeration of lymphocytes, as well as staining for CD8, FOXP3, CD68, CD163, PDL1, and CTLA4 characterized immune infiltrate. Neoantigens were determined by analysis of whole-exome sequencing data. Random-forest clustering was employed to define multimarker subtypes, with univariate and multivariate analyses interrogating prognostic significance.Results: PDAC cases exhibited distinct stromal phenotypes that were associated with prognosis, glycolytic and hypoxic biomarkers, and immune infiltrate composition. Immune infiltrate was diverse among PDAC cases and enrichment for M2 macrophages and select immune checkpoints regulators were specifically associated with survival. Composite analysis with neoantigen burden, immunologic, and stromal features defined novel subtypes of PDAC that could have bearing on sensitivity to immunologic therapy approaches. In addition, a subtype with low levels of neoantigens and minimal lymphocyte infiltrate was associated with improved overall survival.Conclusions: The mutational burden of PDAC is associated with distinct immunosuppressive mechanisms that are conditioned by the tumor stromal environment. The defined subtypes have significance for utilizing immunotherapy in the treatment of PDAC. Clin Cancer Res; 23(15); 4429-40. ©2017 AACR.
Tissue and Peripheral T-cell Repertoire Predicts Immunotherapy Response and Progression-Free Survival in NSCLC Patients.

Manuel Pino-Gonzalez,Martin Lazaro-Quintela,Irene Alonso-Alvarez,Maria Gallardo-Gomez,Laura Juaneda-Magdalena,Alejandro Francisco-Fernandez,Silvia Calabuig-Farinas,Eloisa Jantus-Lewintre,Monica Martinez-Fernandez

DOI: https://doi.org/10.1101/2024.08.01.24311282

2024-08-02

Abstract:Immunotherapy has opened new avenues of treatment for patients with advanced non-small cell lung cancer (NSCLC) without previous hope of survival. Unfortunately, only a small percentage of patients benefit from it, and it is still not well understood which tumor characteristics can be used to predict immunotherapy response. As the key cellular effectors of antitumor immunity, T cells are endowed with specialized T cell receptors (TCRs) to recognize and eliminate cancer cells. Here, we evaluated the potential of TCR repertoire as a predictive biomarker in patients treated with immunotherapy. With this aim, advanced NSCLC patients treated with immunotherapy at first-line were included. After obtaining peripheral blood and tissue samples at baseline, next-generation sequencing targeting TCRbeta/gamma was performed. Beyond TCR metrics, clonal space of the most frequent clones was determined. We found a positive association between uneven tumor-infiltrating TCRbeta repertoire and the immunotherapy response. Moreover, the use of various tumor-infiltrating and circulating TRBV/J genes predicted the immunotherapy response. Our results indicate the importance of evaluating tissue and circulating TCRbeta repertoire prior immunotherapy, showing it as a promising immunotherapy response biomarker in NSCLC patients.

Multiple adenocarcinomas in intrathoracic upside-down stomach.

Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma

312P Identification of Neoantigen-Specific T Cell Response and Anti-Tumour Immunity in Pancreatic Cancer

Abstract 3241: Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy

Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor

Abstract 5261: Immunologic signatures of peripheral blood cells in patients with advanced pancreatic cancer under lenvatinib-pembrolizumab maintenance therapy

Abstract 2847: Simultaneous TCR and transcriptomic sequencing of single Tcells defines biological subtypes in pancreatic cancer for adoptive Tcell therapy

Abstract 6397: Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

Circulating Regulatory T Cell Subsets Predict Overall Survival of Patients with Unresectable Pancreatic Cancer.

T Cell Receptor Β‐chain Repertoire Analysis of Tumor‐infiltrating Lymphocytes in Pancreatic Cancer

Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy

Abstract C026: Single-cell multi-omics in pancreatic cancer reveals differential immune evasion mechanisms between prognostic groups

Clinical Significance of Peripheral T-cell Receptor Repertoire Profiling and Individualized Nomograms in Patients with Gastrointestinal Cancer Treated with Anti-Programmed Death 1 Antibody.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Peripheral T-cell receptor repertoire dynamics in small cell lung cancer

Abstract PR-06: Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

PROGNOSTIC AND PREDICTIVE VALUE OF PRE-TREATMENT T-CELL RECEPTORS (TCR) REPERTOIRE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH SINGLE AGENT IMMUNOTHERAPY

Abstract A010: Tumor-reactive T cell clonal dynamics across treatment time points drive resistance and progression to frontline chemoimmunotherapy in advanced gastric cancer

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

Tissue and Peripheral T-cell Repertoire Predicts Immunotherapy Response and Progression-Free Survival in NSCLC Patients.